SPan-1 and Exocrine Pancreatic Carcinoma. The Clinical Role of a New Tumor Marker

Frena, Antonio

doi:10.1177/172460080101600306

Cited by 14 publications

(7 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Others found no effect on the diagnostic sensitivity of CA 19-9 in PDAC [33]. Frena [34] found that CA 19-9 levels were increased in jaundiced patients with chronic pancreatitis and other digestive neoplasms relative to non-jaundiced patients in the same groups, but that this relationship did not occur in patients with pancreatic carcinomas. Several other studies have similarly shown a correlation between CA 19-9 and bilirubin in benign diseases but no such relationship in patients with a pancreaticobiliary malignancy [35-37].…”

Section: Ten-year Single Institution Experiencementioning

confidence: 99%

The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates

Poruk¹,

Gay²,

Brown³

et al. 2013

CMM

214

170

View full text Add to dashboard Cite

CA 19-9 and CEA are the most commonly used biomarkers for diagnosis and management of patients with pancreatic cancer. Since the original compendium by Steinberg in 1990, numerous studies have reported the use of CA 19-9 and, to a lesser extent, CEA in the diagnosis of pancreatic cancer. Here we update an evaluation of the accuracy of CA 19-9 and CEA, and, unlike previous reviews, focus on discrimination between malignant and benign disease instead of normal controls. In 57 studies involving 3,285 pancreatic carcinoma cases, the combined sensitivity of CA 19-9 was 78.2% and in 37 studies involving 1,882 cases with benign pancreatic disease the specificity of CA 19-9 was 82.8%. From the combined analysis of studies reporting CEA, the sensitivity was 44.2% (1,324 cases) and the specificity was 84.8% (656 cases). These measurements more appropriately reflect the expected biomarker accuracy in the differential diagnosis of patients with periampullary diseases. We also present a summary of the use of CA 19-9 as a prognostic tool and evaluate CA 19-9 diagnostic and prognostic utility in a 10-year, single institution experience.

show abstract

Section: Ten-year Single Institution Experiencementioning

confidence: 99%

The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates

Poruk¹,

Gay²,

Brown³

et al. 2013

CMM

214

170

View full text Add to dashboard Cite

show abstract

“…Dismal prognosis of PC yields from asymptomatic early stages, speedy metastatic progression, lack of effective treatment protocols, early loco regional recurrence, and absence of clinically useful biomarker(s) that can detect PC in its precursor form(s) ( Ballehaninna and Chamberlain, 2012 ). Studies have indicated a promising 70% 5-year survival for cases where incidental detections happened for stage I pancreatic tumors that were still confined to pancreas ( Frena, 2001 ; Schneider and Schulze, 2003 ). Therefore, it only seems rational to aggressively screen for early detection of PDAC.…”

Section: Introductionmentioning

confidence: 99%

A Transcriptomics-Based Meta-Analysis Combined With Machine Learning Identifies a Secretory Biomarker Panel for Diagnosis of Pancreatic Adenocarcinoma

Khatri

Bhasin

2020

Front. Genet.

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is generally incurable due to the late diagnosis and absence of markers that are concordant with expression in several sample sources (i.e., tissue, blood, plasma) and platforms (i.e., Microarray, sequencing). We optimized meta-analysis of 19 PDAC (tissue and blood) transcriptome studies from multiple platforms. The key biomarkers for PDAC diagnosis with secretory potential were identified and validated in different cohorts. Machine learning approach i.e., support vector machine supported by leave-one-out cross-validation was used to build and test the classifier. We identified a 9-gene panel (IFI27, ITGB5, CTSD, EFNA4, GGH, PLBD1, HTATIP2, IL1R2, CTSA) that achieved ∼0.92 average sensitivity and ∼0.90 average specificity in distinguishing PDAC from healthy samples in five training sets using cross-validation. These markers were also validated in proteomics and single-cell transcriptomics studies suggesting their prognostic role in the diagnosis of PDAC. Our 9-gene classifier can not only clearly discriminate between better and poor survivors but can also precisely discriminate PDAC from chronic pancreatitis (AUC = 0.95), early stages of progression [Stage I and II (AUC = 0.82), IPMA and IPMN (AUC = 1), and IPMC (AUC = 0.81)]. The 9-gene marker outperformed the previously known markers in blood studies particularly (AUC = 0.84). The discrimination of PDAC from early precursor lesions in non-malignant tissue (AUC > 0.81) and peripheral blood (AUC > 0.80) may assist in an early diagnosis of PDAC in blood samples and thus will also facilitate risk stratification upon validation in clinical trials.

show abstract

“…This tumor marker has already been investigated as a diagnostic and prognostic tool for PDAC. It is little used however, because its sensitivity and specificity are no higher than those of existing tumor markers such as CA19-9 [51,52]. In the study by Tsutsumi et al, a SPAN-1 change pattern was found similar to that of CA19-9.…”

Section: Resultsmentioning

confidence: 99%

Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients

Sijde

Vietsch

Mustafa

et al. 2019

Cancers

View full text Add to dashboard Cite

Pancreatic cancer is a lethal disease with increasing incidence. Most patients present with advanced disease, for which palliative systemic chemotherapy is the only therapeutic option. Despite improved median survival rates with FOLFIRINOX or gemcitabine chemotherapy compared to the best supportive care, many individual patients may not benefit from chemotherapy. Biomarkers are needed to predict who will benefit from chemotherapy and to monitor a patient’s response to chemotherapy. This review summarizes current research and future perspectives on circulating biomarkers for systemic chemotherapy response.

show abstract

SPan-1 and Exocrine Pancreatic Carcinoma. The Clinical Role of a New Tumor Marker

Cited by 14 publications

References 47 publications

The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates

The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates

A Transcriptomics-Based Meta-Analysis Combined With Machine Learning Identifies a Secretory Biomarker Panel for Diagnosis of Pancreatic Adenocarcinoma

Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients

Contact Info

Product

Resources

About